Whole orbital tissue culture identifies imatinib mesylate and adalimumab as potential therapeutics for Graves' ophthalmopathy

British Journal of Ophthalmology

Volumn 95, Issue 5, 2011, Pages 735-738

  Van Steensel, Leendert ^a   Martin Van Hagen, P ^a,b   Paridaens, Dion ^b   Kuijpers, Robert W A M ^a   Van Den Bosch, Willem A ^b   Drexhage, Hemmo A ^a   Hooijkaas, Herbert ^a   Dik, Willem A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ROTTERDAM EYE HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; HYALURONIC ACID; IMATINIB; INTERLEUKIN 6; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR B; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOCRINE OPHTHALMOPATHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INHIBITION KINETICS; ORBIT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPERNATANT; TISSUE CULTURE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; GENE EXPRESSION REGULATION; GRAVES OPHTHALMOPATHY; HUMANS; HYALURONIC ACID; INTERLEUKIN-6; MALE; PIPERAZINES; PYRIMIDINES; RNA, MESSENGER; TISSUE CULTURE TECHNIQUES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79955024423     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2010.192302     Document Type: Article

References (24)

1. Ong VH, Denton CP. Innovative therapies for systemic sclerosis. Curr Opin Rheumatol 2010;22:264-72.
2. Buch MH. Sequential use of biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 2010;22:321-9.
3. Kunz M. Current treatment of psoriasis with biologics. Curr Drug Discov Technol 2009;6:231-40.
4. Sfikakis PP, Gorgoulis VG, Katsiari CG, et al. Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) 2008;47:735-7. (Pubitemid 351619226)
5. van Daele PL, Dik WA, Thio HB, et al. Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis Rheum 2008;58:2549-52.
6. Akhmetshina A, Venalis P, Dees C, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009;60:219-24.
7. Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol 2007;18:481-6. (Pubitemid 351339402)
8. Baeten D, van Hagen PM. Rational therapy and evidence-based medicine: lessons from rare, refractory immune-mediated inflammatory diseases. Ann Rheum Dis 2010;69:2067-73.
9. Bahn RS. Graves' ophthalmopathy. N Engl J Med 2010;362:726-38.
10. van Steensel L, Dik WA. The orbital fibroblast: a key player and target for therapy in Graves' ophthalmopathy. Orbit 2010;29:202-6.
11. van Steensel L, Paridaens D, Schrijver B, et al. Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves' ophthalmopathy. Invest Ophthalmol Vis Sci 2009;50:3091-8.
12. van Steensel L, Paridaens D, Dingjan GM, et al. Platelet-derived growth factor-BB: a stimulus for cytokine production by orbital fibroblasts in Graves' ophthalmopathy. Invest Ophthalmol Vis Sci 2010;51:1002-7.
13. Paridaens D, van den Bosch WA, van der Loos TL, et al. The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye (Lond) 2005;19:1286-9. (Pubitemid 43148503)
14. Durrani OM, Reuser TQ, Murray PI. Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy. Orbit 2005;24:117-19. (Pubitemid 40904566)
15. El Fassi D, Nielsen CH, Bonnema SJ, et al. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. J Clin Endocrinol Metab 2007;92:1769-72. (Pubitemid 46997186)
16. Weetman AP, Cohen S, Gatter KC, et al. Immunohistochemical analysis of the retrobulbar tissues in Graves' ophthalmopathy. Clin Exp Immunol 1989;75:222-7. (Pubitemid 19074250)
17. Boschi A, Daumerie C, Spiritus M, et al. Quantification of cells expressing the thyrotropin receptor in extraocular muscles in thyroid associated orbitopathy. Br J Ophthalmol 2005;89:724-9. (Pubitemid 40780581)
18. Wakelkamp IM, Bakker O, Baldeschi L, et al. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients. Clin Endocrinol (Oxf) 2003;58:280-7. (Pubitemid 36308115)
19. Molnar I, Balazs C. High circulating IL-6 level in Graves' ophthalmopathy. Autoimmunity 1997;25:91-6. (Pubitemid 27196644)
20. Wakelkamp IM, Gerding MN, Van Der Meer JW, et al. Both Th1- and Th2-derived cytokines in serum are elevated in Graves' ophthalmopathy. Clin Exp Immunol 2000;121:453-7.
21. Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol 1998;16:249-84. (Pubitemid 28102256)
22. Jyonouchi SC, Valyasevi RW, Harteneck DA, et al. Interleukin-6 stimulates thyrotropin receptor expression in human orbital preadipocyte fibroblasts from patients with Graves' ophthalmopathy. Thyroid 2001;11:929-34. (Pubitemid 33020179)
23. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7. (Pubitemid 32267972)
24. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009;137:1628-40.